Study Confirms Excellent Prognosis for Stage I Seminoma
the Cancer Therapy Advisor take:
Patients presenting with stage I seminoma who received a single cycle of adjuvant carboplatin following inguinal orchidectomy have an excellent prognosis, a new study published online ahead of print in the journal Annals of Oncology has shown.
For the retrospective analysis, researchers identified 517 patients with stage I testicular seminomatous germ cell tumor who received one cycle of adjuvant carboplatin South Central England between 1996 and 2013.
Results showed that with a median follow-up of 47.2 months, the 5-year estimated relapse-free survival was 95.0% (95% CI: 92.8, 97.3). In the 21 patients that relapsed, the median time to relapse was 22.7 months. Only four patients experienced a relapse beyond 3 years and 95% of relapsed patients had retroperitoneal lymph node metastases.
Researchers found that 76% of those that relapsed had elevated tumor markers at the time of relapse. Nearly 4% of all patients developed a new contralateral testicular germ cell cancer.
The findings suggest that increasing tumor size is associated with an increased risk of post-chemotherapy relapse.
Patients presenting with stage I seminoma who received adjuvant carboplatin following inguinal orchidectomy have excellent prognosis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Bleeding Disorder Treatments: Hemophilia A
- Pazopanib Plus Cetuximab May Be Effective and Well-Tolerated in Head and Neck Cancer
- FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
- Bleeding Disorder Treatments: Hemophilia B
- Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific